Racial comparison of p53 alterations in breast cancer: Difference in prognostic value

In Vivo

Volumn 10, Issue 2, 1996, Pages 169-174

  Shiao, Yih Horng ^a,c   Chen, Vivien W ^b   Wu, Xiao Cheng ^b   Scheer, W Douglas ^b   Lehmann, H Peter ^b   Malcom, Gray T ^b   Boudreau, Donald A ^b   Ruiz, Bernardo ^b   Correa, Pelayo ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Breast cancer; p53 alterations; Racial difference; Survival

Indexed keywords

PROTEIN P53;

ARTICLE; BREAST CANCER; CANCER SURVIVAL; CAUCASIAN; FEMALE; GENE MUTATION; HUMAN; NEGRO; PROGNOSIS; RACE DIFFERENCE; UNITED STATES;

EID: 0030071001     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. National Cancer Institute: Cancer among blacks and other minorities: Statistical profiles, NIH Pub. No. 86-2785. Washington DC: National Cancer Institute, 1986.
2. Miller BA, Ries LAG, Hankey BF, Kosary CL, Harris A, Devesa SS, and Edwards BK: SEER Cancer Statistics Review: 1973-1990. Bethesda, MD: National Cancer Institute, NIH publication 93-2789, 1993.
3. Sondik EJ: Breast cancer trends: Incidence, mortality, and survival. Cancer 74: 995-999, 1994.
4. Howard J, Hankey BF, Greenberg RS, Austin DF, Correa P, Chen VW, and Durako S: A collaborative study of differences in the survival rates of black patients and white patients with cancer. Cancer 69: 2349-2360, 1992.
5. Hunter CP, Redmond CK, Chen VW, Austin DF, Greenberg RS, Correa P, Muss HB, Forman MR, Wesley MN, and Blacklow RS: Breast cancer: factors associated with stage at diagnosis in black and white women. J Natl Cancer Inst 85: 1129-1137, 1993.
6. Chen VW, Correa P, Kurman RJ, Wu XC, Eley JW, Austin D, Muss H, Hunter C, Redmond C, Sobhan M, Coates R, Reynolds P, Herman AA, and Edwards B: Histologic characteristics of breast carcinoma in blacks and whites. Cancer Epidemiol Biomarkers and Prevention 3: 127-135, 1994.
7. Eley JW, Hill HA, Chen VW, Austin DF, Wesley MN, Muss HB, Greenberg RS, Coates RJ, Correa P, Redmond CK, Hunter CP, Herman AA, Kurman R, Blacklow R, Shapiro S, and Edwards BK: Racial differences in survival from breast cancer: results of the National Cancer Institute Black/White Cancer Survival Study. J Am Med Assoc 272: 947-954, 1994.
8. Isola J, Visakorpi T, Holli K, Kallioniemi O-P: Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 84: 1109-1114, 1992.
9. Allred DC, Clark GM, Elledge R, Fuqua SAW, Brown RW, Chamness GC, Osborne CK, and McGuire WL: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85: 200-206, 1993.
10. Andersen TI, Holm R, Nesland JM, Heimdal KR, Ottestad L, and Borresen AL: Prognostic significance of p53 alterations in breast carcinoma. Br J Cancer 68: 540-548, 1993.
11. Saitoh S, Cunningham J, De Vries EMG, McGovern RM, Schroeder JJ, Hartmann A, Blaszyk H, Wold LE, Schaid D, Sommer SS, and Kovach JS: p53 gene mutations in breast cancers in midwestern US women: null as well as missense-type mutations are associated with poor prognosis. Oncogene 9: 2869-2875, 1994.
12. Ozbun MA and Butel JS: Tumor suppressor pS3 mutations and breast cancer: A critical analysis. Adv Cancer Res 66: 71-141, 1995.
13. Fung CY and Fisher DE: p53: From molecular mechanisms to prognosis in cancer. J Clin Oncol 13: 808-811, 1995.
14. Lowe SW, Ruley HE, Jacks T, and Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967, 1993.
15. Gotz C and Montenarh M: p53 and its implication in apoptosis (Review). Int J Oncol 6: 1129-1135, 1995.
16. Lemoine NR: Molecular biology of breast cancer. Ann Oncol 5(suppl 4): 31-37, 1994.
17. Slingerland JM, Jenkins JR, and Benchimol S: The transforming and suppressor functions of p53 alleles: effects of mutations that disrupt phosphorylation, oligomerization and nuclear translocation. EMBO J 12: 1029-1037, 1993.
18. Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M, Finlay C, and Levine AJ: Gain of function mutations in p53. Nature Genetics 4: 42-46, 1993.
19. Forrester K, Lupold SE, Ott VL, Chay CH, Band V, Wang XW, and Harris CC: Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent. Oncogene 10: 2103-2111, 1995.
20. Matlashewski G, Banks L, Pim D, Crawford L: Analysis of human p53 proteins and mRNA levels in normal and transformed cells. Eur J Biochem 154: 665-672, 1986.
21. Fritsche M, Haessler C, Brandner G: Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 8: 307-318, 1993.
22. Reihsaus E, Kohler M, Kraiss S, Oren M, Monteharn M: Regulation of the level of the oncoprotein p53 in non-transformed and transformed cells. Oncogene 5: 137-145, 1990.
23. Bodner SM, Minna JD, Jensen SM, D'Amico D, Carbone D, Mitsudomi T, Fedorko J, Buchhagen DL, Nau MM, Gazdar AF, and Mitsudomi T, Fedorko J, Buchhagen DL, Nau MM, Gazdar AF, and Linnoila RI: Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene 7: 743-749, 1992.
24. Louis DN, von Deimling A, Chung RY, Rubio M-P, Whaley JM, Eibl RH, Ohgaki H, Wiestler OD, Thor AD, and Seizinger BR: Comparative study of p53 gene and protein alterations in human astrocytic tumors. J Neuropathol Exp Neurol 52: 31-38, 1993.
25. Shiao YH, Chen VW, Scheer WD, Cheng XC, and Correa P: Racial disparity in the association of p53 gene alterations with breast cancer survival. Cancer Res 55: 1485-1490, 1995.
26. Rugge M, Shiao YH, Correa P, Baffa R, and Di Mario F: Immunohistochemical evidence of p53 overexpression in gastric epithelial dysplasia. Cancer Epidemiol Biomarkers & Prevention 1: 551-554, 1992.
27. Kaplan EL and Meier P: Nonparametric estimation from incomplete data. J Am Stat Assoc 54: 457-481, 1958.
28. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemotherapy Reports 50: 163-170, 1966.
29. Cox DR: Regression models and life tables. J Roy Stat Soc 34: 187-220, 1972.
30. Elledge RM, Clark GM, Chamness GC, and Osborne CK: Tumor biologic factors and breast cancer prognosis among white, hispanic, and black women in the United States. J Natl Cancer Inst 86: 705-712, 1994.
31. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, and Jacks T: p53 status and the efficacy of cancer therapy in vivo. Science 266: 807-810, 1994.
32. Fan S, Smith ML, Rivet DJ II, Duba D, Zhan Q, Kohn KW, Fornace AJ Jr: Disruption of p53 function sensitizes breast cancer MCF7 cells to cisplatin and pentoxifylline. Cancer Res 55: 1649-1654, 1995.
33. Balcer-Kubiczek EK, Yin J, Lin K, Harrison GH, Abraham JM, and Meltzer SJ: p53 mutational status and survival of human breast cancer MCF-7 cell variants after exposure to x rays or fission neutrons. Radiation Res 142: 256-262, 1995.
34. Koechli OR, Schaer GN, Seifert B, Hornung R, Haller U, Eppenberger U, and Mueller H: Mutant p53 protein associated with chemosensitivity in breast cancer specimens. Lancet 344: 1647-1648, 1994.16
35. Petty RD, Cree IA, Sutherland LA, Hunter EM, Lane DP, Preece PE, and Andreotti PE: Expression of the p53 tumour suppressor gene product is a determinant of chemosensitivity. Biochem Biophy Res Comm 199: 264-270, 1994.
36. Makris A, Powles TJ, Dowsett M, and Allred C: p53 protein overexpression and chemosensitivity in breast cancer (letter). Lancet 345: 1181-1182, 1995.
37. Mathieu M-C. Koscielny S, Le Bihan M-L., Spielmann M, Arriagada R, and the Institute Gustave-Roussy Breast Cancer Group: p53 protein overexpression and chemosensitivity in breast cancer (letter). Lancet 345: 11-82, 1995.
38. Elledge RM, Gray R, Mansour E, Yu Y, Clark GM, Ravdin P, Osborne CK, Gilchrist K, Davidson NE, Robert N, Tormey DC, and Allred DC: Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. J Natl Cancer Inst 87: 1254-1256, 1995.